医学
医学物理学
肝细胞癌
选择性内照射治疗
临床试验
微球
德尔菲法
多学科方法
内科学
计算机科学
社会科学
化学工程
工程类
社会学
人工智能
作者
Riad Salem,Siddharth A. Padia,Mandy M. Lam,Carlo Chiesa,Paul Haste,Bruno Sangro,Beau B. Toskich,Kirk D. Fowers,Joseph M. Herman,S. Cheenu Kappadath,TW Leung,Daniel Y. Sze,Edward Kim,Etienne Garin
标识
DOI:10.1007/s00259-022-05956-w
摘要
In light of recently published clinical reports and trials, the TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to review new data and to update previously published clinical and dosimetric recommendations for the treatment of hepatocellular carcinoma (HCC).The TheraSphere Global DSC is comprised of health care providers across multiple disciplines involved in the treatment of HCC with yttrium-90 (Y-90) glass microsphere-based transarterial radioembolization (TARE). Literature published between January 2019 and September 2021 was reviewed, discussed, and adjudicated by the Delphi method. Recommendations included in this updated document incorporate both the results of the literature review and the expert opinion and experience of members of the committee.Committee discussion and consensus led to the expansion of recommendations to apply to five common clinical scenarios in patients with HCC to support more individualized efficacious treatment with Y-90 glass microspheres. Existing clinical scenarios were updated to reflect recent developments in dosimetry approaches and broader treatment paradigms evolving for patients presenting with HCC.Updated consensus recommendations are provided to guide clinical and dosimetric approaches for the use of Y-90 glass microsphere TARE in HCC, accounting for disease presentation, tumor biology, and treatment intent.
科研通智能强力驱动
Strongly Powered by AbleSci AI